Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Highlights From the American Society for Radiation Oncology 2014 Annual Meeticonfereng

TOP - October 2014, Vol 7, No 4 - Conference Correspondent
Alice Goodman

The annual meeting of the American Society for Radiation Oncology (ASTRO) took place in San Francisco, California, on September 14-17, 2014. The meeting draws more than 11,000 attendees, bringing together clinicians, scientists, and researchers from all oncology disciplines. ASTRO highlights how technology and biology advance the field of radiation oncology and improve outcomes and quality of life for patients. As ASTRO’s needs statement for the annual meeting points out, nearly two-thirds of the estimated 1.6 million people who will be diagnosed with cancer this year will receive radiation therapy - this makes it imperative that all members of the multidisciplinary team be aware of best practices. Below are summaries of some highlights from the meeting.

ASTRO’s Choosing Wisely List
Continuing its participation in the American Board of Internal Medicine’s Choosing Wisely campaign, ASTRO released its second list of 5 radiation treatments that should be questioned and not used routinely in clinical practice.

The 2014 list follows:

  • Don’t recommend radiation following hysterectomy for endometrial cancer patients with low-risk disease.
  • Don’t routinely offer radiation therapy for patients who have resected non–small cell lung cancer (NSCLC), negative margins, N0-1 disease.
  • Don’t initiate noncurative radiation therapy without defining the goals of treatment with the patient and considering palliative care.
  • Don’t routinely recommend follow-up mammograms more often than annually for women who have had radiotherapy following breast conserving surgery.
  • Don’t routinely add adjuvant whole brain radiation to stereotactic radiosurgery for limited brain metastases.
Along with ASTRO’s 2013 list, this totals 10 radiation treatments that should not be used routinely without thorough discussion between patients and physicians.

ASTRO’s 2013 Choosing Wisely list included these recommendations:

  • Don’t initiate whole breast radiotherapy as a part of breast conservation therapy in women age ≥50 with early stage invasive breast cancer without considering shorter treatment schedules.
  • Don’t initiate management of low-risk prostate cancer without discussing active surveillance.
  • Don’t routinely use extended fractionation schemes (>10 fractions) for palliation of bone metastases.
  • Don’t routinely recommend proton beam therapy for prostate cancer outside of a prospective clinical trial or registry.
  • Don’t routinely use intensity-modulated radiotherapy (IMRT) to deliver whole breast radiotherapy as part of breast conservation therapy.
2014 ASTRO President Bruce Haffty, MD, was quick to note that there are specific circumstances where these treatments are warranted but said that they should not be prescribed routinely. He also noted that there is some evidence that clinical practice has shifted as a result of the campaign.

Choosing Wisely is aimed at reducing unnecessary healthcare expenditures while at the same time providing appropriate high-quality care. To see all the recommendations from medical societies in the United States, go to www.choosingwisely.org.

Related Items
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA Abstracts
Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA Abstracts
Graft-versus-Host Disease: Breakthroughs on the Horizon
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA Abstracts
Basket Clinical Trials: A New Era in Cancer Treatment
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA Abstracts
Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA Abstracts
Chemotherapy Treatment Considerations in Special Patient Populations
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA Abstracts
Nivolumab/Ipilimumab Combination Extends Survival for Patients with Melanoma
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Melanoma, AACR News, Conference Correspondent
Pursuit of Biomarkers for CDK4/CDK6 Response Fails
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in AACR News, Conference Correspondent
Abemaciclib Moves Forward in Metastatic Breast Cancer
Phoebe Starr
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in AACR News, Conference Correspondent
Updated NCCN Guidelines for Neuroendocrine Tumors and Carcinoid Syndrome Features New Therapies
Wayne Kuznar
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, NCCN News, NCCN
Last modified: April 27, 2020